Oxeglitazar
| Oxeglitazar.svg | |
Oxeglitazar is a pharmaceutical compound that was investigated for its potential use in the treatment of type 2 diabetes mellitus. It belongs to the class of drugs known as thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR) agonists. Oxeglitazar is a dual PPAR agonist, meaning it activates both the PPAR-alpha and PPAR-gamma receptors.
Mechanism of Action[edit | edit source]
Oxeglitazar works by modulating the activity of PPAR-alpha and PPAR-gamma receptors. These receptors are nuclear hormone receptors that regulate the expression of genes involved in glucose and lipid metabolism. Activation of PPAR-gamma improves insulin sensitivity, which helps lower blood glucose levels. PPAR-alpha activation leads to increased fatty acid oxidation and improved lipid profiles.
Clinical Development[edit | edit source]
Oxeglitazar was developed with the aim of providing a therapeutic option that could address both hyperglycemia and dyslipidemia in patients with type 2 diabetes. However, like many other drugs in the TZD class, its development was halted due to concerns over adverse effects, including potential cardiovascular risks and liver toxicity.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of oxeglitazar includes its absorption, distribution, metabolism, and excretion. It is typically administered orally, and its bioavailability is influenced by factors such as food intake. Oxeglitazar is metabolized in the liver, and its metabolites are excreted primarily via the kidneys.
Adverse Effects[edit | edit source]
Common adverse effects associated with thiazolidinediones, including oxeglitazar, are weight gain, edema, and an increased risk of heart failure. These side effects are primarily due to fluid retention and changes in adipose tissue distribution.
Regulatory Status[edit | edit source]
As of the latest updates, oxeglitazar has not been approved for clinical use by major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its development was discontinued in the clinical trial phase.
Also see[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
